Opinion|Videos|June 25, 2024
Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What factors do you consider when choosing between fixed-duration and continuous BTK inhibitor therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
- How do you weigh the pros and cons of each approach, including treatment logistics and time off therapy?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Five Under 5: Top Oncology Videos for the Week of 8/16
4
The OncFive: Top Oncology Articles for the Week of 8/16
5